Details for Patent: 9,555,048
Which drugs does patent 9,555,048 protect, and when does it expire?
Patent 9,555,048 protects ZILRETTA and is included in one NDA.
This patent has fifty-one patent family members in twenty-two countries.
Summary for Patent: 9,555,048
| Title: | Corticosteroids for the treatment of joint pain | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Pacira Therapeutics Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/461,884 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 9,555,048: Scope, Claims, Expiration, and Zilretta Patent LandscapeUS Patent 9,555,048 protects a method of treating pain or inflammation with injectable, controlled-release triamcinolone acetonide microparticles. The claim requires a specific PLGA polymer profile, a 22% to 28% triamcinolone loading, and sustained corticosteroid release. The patent is closely associated with Flexion Therapeutics' Zilretta, an extended-release intra-articular triamcinolone acetonide product later acquired by Pacira BioSciences. The patent's principal commercial value is concentrated in the formulation combination rather than in triamcinolone acetonide itself. The strongest infringement risk applies to injectable PLGA microsphere products that reproduce the claimed drug loading, polymer molecular weight, lactic acid:glycolic acid ratio, particle size, and sustained-release characteristics. What does US Patent 9,555,048 protect?US 9,555,048 is a method-of-treatment patent. Its independent claim requires all of the following:
The patent does not broadly cover every injectable triamcinolone formulation. A competing product using a suspension, liposome, hydrogel, implant, non-PLGA carrier, or a TCA loading outside the claimed range would not literally satisfy claim 1. The patent's commercial center is a microsphere formulation containing approximately 25% triamcinolone acetonide in a 75:25 PLGA matrix. Zilretta is supplied as a 32 mg extended-release intra-articular triamcinolone acetonide formulation for osteoarthritis pain of the knee. The FDA-approved product uses PLGA microspheres and is reconstituted before intra-articular injection.[1] How do the claims of US 9,555,048 operate?Claim 1: Core formulation and treatment combinationClaim 1 is the controlling claim. It combines a treatment step with detailed formulation specifications. A potential infringer must administer the formulation to a patient, but the formulation must also meet the microsphere, TCA-content, and PLGA limitations. This structure creates several potential design-around positions:
The doctrine of equivalents could still create litigation risk where a product falls narrowly outside a numerical limitation, but the numerical ranges provide a comparatively clear claim-construction framework. Claims 2 and 9: Preferred PLGA chemistryClaim 2 narrows the polymer ratio to 75:25 lactic acid:glycolic acid. This limitation is commercially important because 75:25 PLGA is a conventional composition for long-acting biodegradable microspheres and is associated with the Zilretta formulation. Claim 9 adds an inherent viscosity range of 0.3 to 0.5 dL/g. Inherent viscosity functions as a proxy for polymer molecular weight and solution behavior. It can become a disputed issue in litigation because testing conditions, solvent selection, temperature, and measurement methodology can affect the result. Claims 4, 5, and 6: Intra-articular administration and durationClaims 4 and 5 expressly require one or more intra-articular injections. These claims are narrower than claim 1 and are the most directly aligned with Zilretta's FDA-approved use. Claim 6 requires release of TCA for at least 14 days and up to 90 days after administration to a joint. The claim covers a duration range rather than a single release profile. A product with a release period shorter than 14 days would not meet the literal limitation. Claim 7 adds a functional limitation requiring release for at least 14 days at a rate that does not adversely suppress the hypothalamic-pituitary-adrenal axis. This limitation may create factual disputes over clinical testing, pharmacokinetics, and what constitutes adverse HPA-axis suppression. Claims 8, 10, and 11: Dose, particle size, and PEGClaim 8 narrows the TCA content to a total load dose of 10 to 50 mg. The 32 mg Zilretta dose falls within that range. Claim 10 covers microparticles with a mean diameter of 10 to 100 micrometers. Particle size is relevant to injection performance, syringeability, tissue retention, and release kinetics. Claim 11 covers microparticles containing a PEG moiety. The stated range, "between 25% to 0% weight percent," should be read as a range from 0% to 25% by weight. The wording is internally awkward and could create an interpretation issue, but it is directed to PEG-containing or PEG-modified particles. What diseases and indications are covered by US 9,555,048?Claims 12 through 20 expand the patient and disease categories. The claimed indications include:
The broad disease list does not eliminate the formulation limitations in claim 1. A product must still be an injectable controlled-release TCA microparticle formulation using the specified PLGA characteristics. Claims 13 through 20 are vulnerable to written-description, enablement, and obviousness challenges if asserted against uses far removed from intra-articular therapy. The commercial strength of the patent is greater for joint injections than for the full systemic and dermatologic indication list. When does US Patent 9,555,048 expire?
The operative expiration date should be confirmed against the USPTO Patent Center and the FDA Orange Book listing because patent-term adjustment can change the ordinary twenty-year calculation. Patent expiration does not automatically authorize commercial launch if other listed patents, regulatory exclusivities, injunctions, or approval requirements remain relevant.[2][3] What is the Orange Book status of US 9,555,048?The patent has been associated with Zilretta's FDA patent listings. Orange Book relevance depends on whether the patent claims the approved drug, an approved method of use, or both. For Zilretta, the most important listed claims are those directed to extended-release triamcinolone acetonide microspheres administered by intra-articular injection. An ANDA applicant seeking approval before expiration would generally need to address listed patents through one of the following certifications:
A Paragraph IV notice would expose the applicant to Hatch-Waxman litigation. The filing of a qualifying patent-infringement action within 45 days can trigger a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions.[4] Zilretta's complex injectable microsphere formulation also creates a technical barrier that is separate from Orange Book patent risk. A conventional ANDA must demonstrate pharmaceutical equivalence and bioequivalence, while long-acting injectable products can require difficult in vitro release, particle characterization, device, and pharmacokinetic comparisons. What related patents protect Zilretta and extended-release triamcinolone?The relevant patent estate should be analyzed as a family rather than through US 9,555,048 alone.
Public patent records should be reviewed for continuations, divisionals, and continuation-in-part applications. A continuation can issue after US 9,555,048 and carry claims that are narrower but commercially more useful, particularly claims directed to the 32 mg intra-articular product or defined manufacturing conditions. How strong is the patent estate for Zilretta?The estate is strongest against a directly substitutable extended-release TCA microsphere product using PLGA and a similar drug loading. Strengths
Weaknesses
What generic entry risks exist for Zilretta?A generic or follow-on entrant faces four separate risk layers:
A Paragraph IV challenger could avoid literal infringement by changing the PLGA ratio or TCA loading. That strategy would shift the dispute toward the doctrine of equivalents, formulation performance, and whether the modified product remains pharmaceutically equivalent to Zilretta. A 505(b)(2) pathway could be relevant for a differentiated long-acting TCA injectable, but it would not eliminate patent litigation risk. The applicant would still need to address listed patents and demonstrate safety, efficacy, and quality for the proposed product. Which companies are challenging or competing with Zilretta?Zilretta competes primarily with conventional intra-articular corticosteroids, including immediate-release triamcinolone acetonide products marketed by multiple generic manufacturers. Those products are not necessarily direct patent challengers because they do not use the claimed controlled-release PLGA microsphere technology. The more relevant competitive categories are:
A conventional triamcinolone injection generally does not practice claim 1 because it lacks PLGA controlled-release microparticles. It may compete commercially while remaining outside the patent's literal scope. What litigation and licensing events affect the patent landscape?Flexion Therapeutics was acquired by Pacira BioSciences in 2021 in a transaction valued at approximately $1.375 billion. The acquisition transferred Zilretta and Flexion's related intellectual property and commercial rights to Pacira.[5] The acquisition is commercially important because Pacira has an economic incentive to enforce the patent estate through the period before expected expiration. The principal legal questions for any challenger would be infringement of the formulation limitations, validity of the numerical ranges, enablement of the broad indication claims, and the regulatory status of the proposed product. No separate commercial license is necessary to explain current Zilretta ownership. Pacira is the relevant commercial patent owner or successor-in-interest for the Flexion Zilretta portfolio. What is the revenue exposure from US 9,555,048?The patent protects a product with material commercial value to Pacira, but it does not protect the entire intra-articular corticosteroid market. Revenue exposure is therefore product-specific. Zilretta sales have been reported as a distinct product category in Pacira's public filings. The product's value depends on continued differentiation from low-cost immediate-release corticosteroids, physician adoption, reimbursement, and the absence of a therapeutically substitutable long-acting generic.[5] The commercial impact of a successful challenge would likely be asymmetric:
Key Takeaways
FAQs About US Patent 9,555,048 and ZilrettaIs US 9,555,048 a composition patent?No. Its principal independent claim is a method-of-treatment claim requiring administration of a specified injectable TCA/PLGA microparticle formulation. Does a standard triamcinolone acetonide injection infringe US 9,555,048?Generally, no. A standard immediate-release injection lacks the claimed controlled-release PLGA microparticle matrix. Does the patent cover all intra-articular corticosteroid injections?No. It covers intra-articular administration only when the formulation satisfies the claimed TCA loading, PLGA molecular-weight, polymer-ratio, and microparticle requirements. Can a competitor avoid the patent by using a different biodegradable polymer?A different polymer would not literally satisfy the PLGA limitation in claim 1. Equivalence and infringement risk would depend on the product's technical characteristics and the specific claim asserted. Is Zilretta protected by patents beyond US 9,555,048?Yes. Zilretta is associated with a broader patent family and related formulation, process, and method-of-use rights. The complete freedom-to-operate analysis requires review of all issued patents, pending continuations, Orange Book listings, and foreign counterparts. References
More… ↓ |
Drugs Protected by US Patent 9,555,048
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacira Pharms Inc | ZILRETTA | triamcinolone acetonide | FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR | 208845-001 | Oct 6, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,555,048
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 082471 | ⤷ Start Trial | |||
| Australia | 2011285691 | ⤷ Start Trial | |||
| Australia | 2012290683 | ⤷ Start Trial | |||
| Australia | 2015268647 | ⤷ Start Trial | |||
| Australia | 2017245408 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
